However, a phase II clinical trial testing TMZ plus veliparib (or placebo) in patients with SCLC showed that SLFN11-positive tumors, as defined by immunohistochemistry (n = 12) had improved progression-free and overall survival relative to patients with SLFN11-negative tumors (69). Here, SLFN11 is linked to small cell lung carcinoma.